Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04792801

PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC

Evaluation of PET TDM FDG-Choline as a Decision-making Tool for Routine Care on Inclusion on the Liver Transplant List for Hepatocellular Carcinoma

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.

Conditions

Interventions

TypeNameDescription
RADIATIONPET TDM FDG-CholinePerforming an FDG TDM PET and a Choline TDM PET at two different times

Timeline

Start date
2021-06-22
Primary completion
2028-06-01
Completion
2028-06-01
First posted
2021-03-11
Last updated
2022-03-15

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04792801. Inclusion in this directory is not an endorsement.